Abstract
Renal cell carcinoma (RCC) is one of the most common cancers in the United States. Recent achievements in translational research have lead to significant developments in treatment strategies for this malignancy. RCC is a richly vascular neoplasm. A better understanding of its biology has helped in the development of antiangiogenic therapy. Vascular endothelial growth factor (VEGF) is the most important molecular target in the treatment of RCC. Patents have been filed for anti-VEGF and other molecular pathways involved in the pathogenesis of RCC.
Keywords: Angiogenesis, renal cell carcinoma, VHL, VEGF, sorafenib, sumitinib, bevacizumab, temsirolimus, mTOR, angiopoietins
Recent Patents on Anti-Cancer Drug Discovery
Title: Anti-Angiogenic Therapy in Renal Cell Carcinoma
Volume: 5 Issue: 1
Author(s): Shree G. Sharma, Sudip Nanda and Santo Longo
Affiliation:
Keywords: Angiogenesis, renal cell carcinoma, VHL, VEGF, sorafenib, sumitinib, bevacizumab, temsirolimus, mTOR, angiopoietins
Abstract: Renal cell carcinoma (RCC) is one of the most common cancers in the United States. Recent achievements in translational research have lead to significant developments in treatment strategies for this malignancy. RCC is a richly vascular neoplasm. A better understanding of its biology has helped in the development of antiangiogenic therapy. Vascular endothelial growth factor (VEGF) is the most important molecular target in the treatment of RCC. Patents have been filed for anti-VEGF and other molecular pathways involved in the pathogenesis of RCC.
Export Options
About this article
Cite this article as:
Sharma G. Shree, Nanda Sudip and Longo Santo, Anti-Angiogenic Therapy in Renal Cell Carcinoma, Recent Patents on Anti-Cancer Drug Discovery 2010; 5 (1) . https://dx.doi.org/10.2174/157489210789702181
DOI https://dx.doi.org/10.2174/157489210789702181 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Signalling Pathways Activated by Ultraviolet Radiation: Role in Ocular and Cutaneous Health
Current Pharmaceutical Design Pharmaceutical Measures to Prevent Doxorubicin-Induced Cardiotoxicity
Mini-Reviews in Medicinal Chemistry Recent Advances and Future Directions in the Management of Metastatic Renal Cell Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Bleomycin and its Role in Inducing Apoptosis and Senescence in Lung Cells - Modulating Effects of Caveolin-1
Current Cancer Drug Targets Current and Future Therapies Targeting the Immune System in Multiple Sclerosis
Current Pharmaceutical Biotechnology Rho Kinase Inhibitors: Potential Treatments for Diabetes and Diabetic Complications
Current Pharmaceutical Design New Targets of Therapy in T-Cell Lymphomas
Current Drug Targets Inducible Nitric Oxide Synthase-Vascular Endothelial Growth Factor Axis: A Potential Target to Inhibit Tumor Angiogenesis by Dietary Agents
Current Cancer Drug Targets An Insight into Purine, Tyrosine and Tryptophan Derived Marine Antineoplastic Alkaloids
Anti-Cancer Agents in Medicinal Chemistry Cancer Stem Cells in Hematological Disorders: Current and Possible New Therapeutic Approaches
Current Pharmaceutical Biotechnology Reactive Oxygen Species, Cancer and Anti-Cancer Therapies
Current Chemical Biology Microgravity Alters Cancer Growth and Progression
Current Cancer Drug Targets Is HIV Involved in the Pathogenesis of Non-Infectious Pulmonary Complications in Infected Patients?
Current HIV Research CXCR4 Receptor as a Promising Target for Oncolytic Drugs
Mini-Reviews in Medicinal Chemistry Is there a Role for Bevacizumab in Non-Glial Tumors?
Current Drug Targets Update on the Use of Biologics in Vasculitides
Current Pharmaceutical Biotechnology Update on the Principles and Novel Local and Systemic Therapies for the Treatment of Non-Infectious Uveitis
Inflammation & Allergy - Drug Targets (Discontinued) Crosstalk between IGF-1R and other Tumor Promoting Pathways
Current Pharmaceutical Design Wnt / β-Catenin Signaling Pathway as Novel Cancer Drug Targets
Current Cancer Drug Targets An Update on Natural Occurrence and Biological Activity of Chromones
Current Medicinal Chemistry